Supply of BENADRYL ORIGINAL oral liquid bottle by Johnson & Johnson Pacific Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was introduced to regulate the supply and quality of therapeutic goods, including medicines, within Australia. The legislation aims to ensure that therapeutic goods are safe, of acceptable quality, and perform as claimed, thereby protecting public health and safety. In this context, the Act provides mechanisms for controlling the import, manufacture, and supply of therapeutic goods, as well as for taking regulatory action against non-compliant products. Section 14 and 14A of the Act, relevant to this gazette notice, allow for specific exemptions under certain conditions, subject to the overarching policy objective of maintaining therapeutic goods standards while facilitating access to necessary treatments. In the notice provided, Dr. Mayada Kaylai, as a delegate of the Secretary to the Department of Health and Ageing, has granted an exemption for a specific product under these sections, ensuring compliance with most standards but temporarily allowing deviation from a particular microbiological standard until June 2013.

Scope and Application

The Therapeutic Goods Act 1989 applies to a broad spectrum of entities and individuals involved in the regulation, manufacture, importation, supply, and advertising of therapeutic goods within Australia. This encompasses pharmaceutical products, medical devices, blood, tissues, and other substances intended for therapeutic use. The Act governs both public and private sector entities, including companies, manufacturers, importers, sponsors, and health professionals, ensuring that all therapeutic goods available in Australia meet safety, quality, and efficacy standards. The Act extends its jurisdiction across the entire Commonwealth, applying uniformly to all states and territories within Australia. However, certain exclusions and exemptions may apply, particularly to research and development activities under specific conditions or for therapeutic goods used in clinical trials, as governed by the Therapeutic Goods (Exempt Therapeutic Goods) Order 2005. Additionally, the application of the Act can be influenced by subordinate instruments such as regulations and orders, which provide further detail on specific requirements and exemptions. These subordinate instruments may address particular aspects of therapeutic goods, such as labelling, advertising, and the scheduling of medicines, thereby extending or restricting the application of the primary Act.

Key Provisions

Section 14 and 14A of the Therapeutic Goods Act 1989 (the Act) provide mechanisms for granting exemptions from certain regulatory requirements for therapeutic goods. In this particular case, Dr. Mayada Kaylai, as a delegate of the Secretary to the Department of Health and Ageing, has exercised her authority under these sections to permit Johnson & Johnson Pacific Pty Ltd to supply a specific product, BENADRYL ORIGINAL oral liquid bottle (AUST R 14114), which does not comply with the Preservative Efficacy Test for Aspergillus niger specified in Section 8 of the Therapeutic Goods Order No. 77 Microbiological Standards for Medicines. This consent is valid only until June 2013 and is conditional upon the product meeting all other aspects of the aforementioned standards. The obligations imposed by the Act on the parties involved are clear. Johnson & Johnson Pacific Pty Ltd must ensure that the product supplied adheres to all other microbiological standards specified in Therapeutic Goods Order No. 77. Furthermore, the exemption granted by Dr. Mayada Kaylai is strictly time-bound, expiring by June 2013, after which the product must comply with all regulatory requirements, including the Preservative Efficacy Test for Aspergillus niger. Additionally, Johnson & Johnson Pacific Pty Ltd must maintain records and documentation that demonstrate compliance with the conditions of the exemption and the broader regulatory framework. Failure to comply with the conditions of the exemption or the terms of the Act can result in significant consequences. The Therapeutic Goods Act 1989 stipulates various offences and penalties for breaches. Specifically, section 15(1) of the Act empowers the delegate to impose fines and other penalties. While the exact penalties are not specified in the given text, under Australian law, breaches of therapeutic goods regulations can lead to substantial fines, imprisonment, or both, depending on the severity of the offence and the discretion of the court. Therefore, it is imperative for Johnson & Johnson Pacific Pty Ltd to adhere strictly to the conditions set forth to avoid potential legal ramifications.